Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Core Insights - Perspective Therapeutics, Inc. reported a business update and full year results for 2025, highlighting advancements in their clinical pipeline and financial status [1][19]. Clinical Pipeline Advancements - The lead program VMT-α-NET is undergoing a multi-center, open-label, dose-finding study for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors (NETs) [2][5]. - Updated interim data from the VMT-α-NET study presented at ASCO-GI 2026 showed a favorable tolerability profile and durable disease control, with 76% of patients in Cohort 1 and 39% in Cohort 2 showing no progression [3][6][7]. - Cohort 3 of the VMT-α-NET study opened in June 2025, allowing for further patient treatment and assessment of dose-limiting toxicities [8][9]. Financial Overview - As of December 31, 2025, the company had approximately $145 million in cash and short-term investments, down from $227 million in 2024, but supplemented by a subsequent equity offering that raised approximately $164 million [19][20]. - Research and development expenses increased by approximately 102% to $84.2 million in 2025, primarily due to heightened clinical activities and personnel costs [22]. - The net loss for 2025 was $103.1 million, or $1.40 per share, compared to a net loss of $79.3 million, or $1.23 per share, in 2024 [26][33]. Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for cancer, utilizing proprietary technology that targets cancer cells with alpha-emitting isotopes [27][28]. - The company is also expanding its manufacturing capabilities to support clinical trials and commercial operations [18].